Studies in recent years have found that the prognosis of IDH-wildtype diffuse lower grade gliomas with EGFR Amp overlapped with that of GBM (Aibaidula et al., 2017; Stichel et al., 2018; Petersen et al., 2021). The gene discussed is IDH1; the disease is glioblastoma.